News Sentiment

NKTR sentiment intelligence

Nektar Therapeutics news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 70.36 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-1.0% over one week, +18.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -1.0% Price digesting
Trend fit Trend active 18.5% over four weeks
Fair value 150.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 42
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 8
Stock Titan 5
PR Newswire 5
simplywall.st 5
ACCESS Newswire 4
Stocktwits 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 17
Regulatory and legal 4
Analyst action 3
Guidance 1
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 67
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Nektar Therapeutics (NASDAQ:NKTR) for potential corporate wrongdoing. The firm encourages stockholders who purchased Nektar securities before February 26, 2025, and still hold them, to connect to assist in the investigation. The

Tone
Negative 10/100
Event
Regulatory and legal
Published
24 Jun 2026 01:12
Source
ACCESS Newswire
Investing.com Direct company coverage

Nektar Therapeutics chief R&D officer sells $336,211 in stock

Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, recently sold 5,538 shares of the company's common stock for $336,211 through a Rule 10b5-1 trading plan. This insider sale follows a significant 617% surge in NKTR shares over the past year. The company is also making

Tone
Negative 36/100
Event
Market update
Published
23 Jun 2026 05:12
Source
Investing.com